MedTrace Logo

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

NCT00306566 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2007-09-20

No results posted yet for this study

Summary

The purpose of this study is to monitor a specific cellular immune response in melanoma patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP vaccine.

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

CYT004-MelQbG10

Sponsors & Collaborators

  • Cytos Biotechnology AG

    lead INDUSTRY

Principal Investigators

  • Danielle Lienard, MD · Centre Pluridisciplinaire d'Oncologie & LICR, CHUV

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306566 on ClinicalTrials.gov